Safety and efficacy of posaconazole in the long-term treatment of azole-refractory oropharyngeal and esophageal candidiasis in patients with HIV infection

HIV Clinical Trials

Volumn 8, Issue 2, 2007, Pages 86-97

  Vazquez, Jose A ^a,g   Skiest, D J ^b,c   Tissot Dupont, H ^d   Lennox, J L ^e   Boparai, N ^f   Isaacs, R ^f  

^a WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^c BAYSTATE MEDICAL CENTER   (United States)

^d HÔPITAL DE LA CONCEPTION   (France)

^e EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^f MERCK RESEARCH LABORATORIES   (United States)

^g Henry Ford Health System Division of Infectious Diseases   (United States)

Author keywords

Esophageal candidiasis; Oropharyngeal candidiasis; Posaconazole

Indexed keywords

FLUCONAZOLE; ITRACONAZOLE; POSACONAZOLE;

ABDOMINAL PAIN; ADULT; ANEMIA; ANXIETY; ARTHRALGIA; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEMOGRAPHY; DIARRHEA; DIZZINESS; DRUG EFFICACY; DRUG FATALITY; DRUG TOLERABILITY; DRUG WITHDRAWAL; ESOPHAGUS CANDIDIASIS; FEMALE; FOLLOW UP; HEADACHE; HEARING IMPAIRMENT; HEART FAILURE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERCHOLESTEROLEMIA; INSOMNIA; JAUNDICE; LEG EDEMA; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MUSCLE CRAMP; MYALGIA; NAUSEA; NEUROPATHY; NEUTROPENIA; OROPHARYNX CANDIDIASIS; PARANOIA; PRIORITY JOURNAL; RASH; SIDE EFFECT; SKIN DISEASE; SWEATING; THRUSH; TOOTH DISCOLORATION; URINARY TRACT OBSTRUCTION; URTICARIA; VOMITING;

ADULT; AIDS-RELATED OPPORTUNISTIC INFECTIONS; ANTIFUNGAL AGENTS; AZOLES; CANDIDA; CANDIDIASIS; CANDIDIASIS, ORAL; DRUG RESISTANCE, FUNGAL; ENZYMES; ESOPHAGEAL DISEASES; FEMALE; HUMANS; LIVER FUNCTION TESTS; MALE; PHARYNGEAL DISEASES; TREATMENT OUTCOME; TRIAZOLES; VOMITING;

EID: 34250731402     PISSN: 15284336     EISSN: None     Source Type: Journal    
DOI: 10.1310/hct0802-86     Document Type: Article

References (35)

1. Fichtenbaum CJ, Powderly WG. Refractory mucosal candidiasis in patients with human immunodeficiency virus infection. Clin Infect Dis. 1998;26:556-565.
2. Darouiche RO. Oropharyngeal and esophageal candidiasis in immunocompromised patients: treatment issues. Clin Infect Dis. 1998;26:259-272.
3. Pappas PG, Rex JH, Sobel JD, et al. Guidelines for treatment of candidiasis. Clin Infect Dis. 2004;38:161-189.
4. Boken DJ, Swindells S, Rinaldi MG. Fluconazole-resistant Candida albicans. Clin Infect Dis. 1993;17:1018-1021.
5. Newman SL, Flanigan TP, Fisher A, Rinaldi MG, Stein M, Vigilante K. Clinically significant mucosal candidiasis resistant to fluconazole treatment in patients with AIDS. Clin Infect Dis. 1994;19:684-686.
6. Saag MS, Fessel WJ, Kaufman CA, et al. Treatment of fluconazole- refractory oropharyngeal candidiasis with itraconazole oral solution in HIV-positive patients. AIDS Res Hum Retroviruses. 1999;15:1413-1417.
7. Cartledge JD, Midgley J, Youle M, Gazzard BG. Itraconazole cyclodextrin solution - effective treatment for HIV-related candidosis unresponsive to other azole therapy [letter]. J Antimicrob Chemother. 1994;33:1071-1073.
8. Phillips P, Zemcov J, Mahmood W, Montaner JS, Craib K, Clarke AM. Itraconazole cyclodextrin solution for fluconazole-refractory oropharyngeal candidiasis in AIDS: correlation of clinical response with in vitro susceptibility. AIDS. 1996;10:1369-1376.
9. Barrett JP, Vardulaki KA, Conlon C, et al. A systematic review of the antifungal effectiveness and tolerability of amphotericin B formulations. Clin Ther. 2003;25:1295-1320.
10. Villarreal NC, Fothergill AW, Kelly C, Patterson JE, Rinaldi MG, Patterson TF. Candida glabrata resistance to caspofungin during therapy. Presented at: 44th Interscience Conference on Antimicrobial Agents and Chemotherapy; October 30, 2004. Abstract #M-1034.
11. Boucher HW, Groll AH, Chiou CC, Walsh TJ. Newer systemic antifungal agents: pharmacokinetics, safety and efficacy. Drugs. 2004;64:1997-2020.
12. Herbrecht R. Posaconazole: a potent, extended-spectrum triazole anti-fungal for the treatment of serious fungal infections. Int J Clin Pract. 2004;58:612-624.
13. Pfaller MA, Messer SA, Hollis RJ, Jones RN. In vitro activities of posaconazole (SCH 56592) compared with those of itraconazole and fluconazole against 3,685 clinical isolates of Candida spp. and Cryptococcus neoformans. Antimicrob Agents Chemother. 2001;45:2862-2864.
14. Barchiesi F, Arzeni D, Fothergill AW, et al. In vitro activities of the new antifungal triazole SCH 56592 against common and emerging yeast pathogens. Antimicrob Agents Chemother. 2000;44:226-229.
15. Pfaller MA, Messer SA, Hollis RJ, et al. In vitro susceptibilities of Candida bloodstream isolates to the new triazole antifungal agents BMS-207147, Sch 56592, and voriconazole. Antimicrob Agents Chemother. 1998;42:3242-3244.
16. Anstead GM, Martinez M, Graybill JR. Control of a Candida glabrata prosthetic endovascular infection with posaconazole. Med Mycol. 2006;44:273-277.
17. Tobón A, Correa AL, Arango M, de Bedout C, Restrepo A. Posaconazole therapy for severe abdominal candidiasis: a case report. Revista Iberoamericana de Micologia. 2004;21:78-80.
18. Raad II, Graybill JR, Bustamante AB et al. Safety of long-term oral posaconazole use in the treatment of refractory invasive fungal infections. Clin Infect Dis. 2006;42:1726-1734.
19. Xiao L, Madison V, Chau AS, Loebenberg D, Palermo RE, McNicholas PM. Three-dimensional models of wild-type and mutated forms of cytochrome P450 14a-sterol demethylases from Aspergillus fumigatus and Candida albicans provide insights into posaconazole binding. Antimicrob Agents Chemother. 2004;48:568-574.
20. Vanden Bossche H, Willemsens G, Marichal P. Anti-Candida drugs - the biochemical basis for their activity. Crit Rev Microbiol. 1987;15:57-72.
21. Skiest DJ, Vazquez JA, Anstead GM, et al. Posaconazole for the treatment of azole-refractory oropharyngeal and esophageal candidiasis in subjects with HIV infection. Clin Infect Dis. 2007;44(4):607-614.
22. Reference Method for Broth Dilution Antifungal Susceptibility Testing of Yeasts; Approved Standards. NCCLS document M27-A2. Wayne, PA: National Committee for Clinical Laboratory Standards; 2002.
23. Kartsonis NA, Saah A, Lipka CJ, Taylor A, Sable CA. Second-line therapy with caspofungin for mucosal or invasive candidiasis: results from the caspofungin compassionate-use study. J Antimicrob Chemother. 2004;53:878-881.
24. Villanueva A, Gotuzzo E, Arathoon EG, et al. A randomized double-blind study of caspofungin versus fluconazole for the treatment of esophageal candidiasis. Am J Med. 2002;113:294-299.
25. Villanueva A, Arathoon EG, Gotuzzo E, Berman RS, DiNubile MJ, Sable CA. A randomized double-blind study of caspofungin versus amphotericin for the treatment of candidal esophagitis. Clin Infect Dis. 2001;33:1529-1535.
26. Arathoon EG, Gotuzzo E, Noriega LM, Berman RS, DiNubile MJ, Sable CA. Randomized, double-blind, multicenter study of caspofungin versus amphotericin B for treatment of oropharyngeal and esophageal candidiases. Antimicrob Agents Chemother. 2002;46:451-457.
27. Miller CD, Lomaestro BW, Park S, Perlin DS. Progressive esophagitis caused by Candida albicans with reduced susceptibility to caspofungin. Pharmacotherapy. 2006;26:877-880.
28. Krogh-Madsen M, Arendrup MC, Heslet L, Knudsen JD. Amphotericin B and caspofungin resistance in Candida glabrata isolates recovered from a critically ill patient. Clin Infect Dis. 2006;42:938-944.
29. Hegener P, Troke PF, Fatkenheuer G, Diehl V, Ruhnke M. Treatment of fluconazole-resistant candidiasis with voriconazole in patients with AIDS. AIDS. 1998;12:2227-2228.
30. Gerzenshtein L, Patel SM, Scarsi KK, Postelnick MJ, Flaherty JP. Breakthrough Candida infections in patients receiving voriconazole. Ann Pharmacother. 2005;39:1342-1345.
31. Alexander BD, Schell WA, Miller JL, Long GD, Perfect JR. Candida glabrata fungemia in transplant patients receiving voriconazole after fluconazole. Transplantation. 2005;80:868-871.
32. Fichtenbaum CJ, Koletar S, Yiannoutsos C, et al. Refractory mucosal candidiasis in advanced human immunodeficiency virus infection. Clin Infect Dis. 2000;30:749-756.
33. Sanglard D, Ischer F, Bille J. Interactions of the azole SCH56592 with Candida albicans multidrug transporters and different cytochrome P450 forms. Presented at: 37th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC); September 28-October 1, 1997; San Diego, California.
34. Vazquez JA, Skiest DJ, Nieto L, et al. A multicenter, randomized trial evaluating posaconazole versus fluconazole for the treatment of oropharyngeal candidiasis in subjects with HIV/AIDS. Clin Infect Dis. 2006;42:1179-1186.
35. Walsh TJ, Gonzalez CE, Piscitelli S, et al. Correlation between in vitro and in vivo antifungal activities in experimental fluconazole-resistant oropharyngeal and esophageal candidiasis. J Clin Microbiol. 2000;38:2369-2373.